Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FAST-02: Results from the second in-human prospective evaluation of single-fraction proton FLASH for symptomatic thoracic bone metastases.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyĀ·2026
Same author

Bioresorbable electrochemical sensors for continuous deep-tissue lactate monitoring in critical care.

Nature communicationsĀ·2026
Same author

Pair-Density Functional Theory Based on Spin-Projected Unrestricted Hartree-Fock Method: A Density-Corrected Version.

Journal of computational chemistryĀ·2026
Same author

Separated Energy Domains in the Sequential Hydration of a Benzonitrile Radical Cation.

Precision chemistryĀ·2026
Same author

Impact of <i>IL6</i> and <i>IL10</i> Genotype on Cytokines and Preeclampsia in a Pregnant Multi-Ethnic Cohort of Women With Overweight and Obesity.

Biological research for nursingĀ·2026
Same author

Physiological super-resolution in situ recording reveals kinetic changes of sympathetic norepinephrine release in heart failure.

Proceedings of the National Academy of Sciences of the United States of AmericaĀ·2026

Related Experiment Video

Updated: Jun 5, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.5K

Clotted Apheresis Hematopoietic Stem Cell Product.

Lefan Zhuang1, Jennifer Woo2, Franchesca Francisco1

  • 1Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.

Journal of Clinical Apheresis
|December 6, 2024
PubMed
Summary

Fresh hematopoietic progenitor cell (HPC) products can unexpectedly clot after collection. This case highlights the potential for rapid clot formation in unprocessed HPC collections, suggesting the need for anticoagulants.

More Related Videos

Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
08:32

Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures

Published on: October 30, 2009

25.2K
Expansion and Enrichment of Gamma-Delta &#947;&#948; T Cells from Apheresed Human Product
11:51

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Published on: September 22, 2021

8.9K

Related Experiment Videos

Last Updated: Jun 5, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.5K
Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
08:32

Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures

Published on: October 30, 2009

25.2K
Expansion and Enrichment of Gamma-Delta &#947;&#948; T Cells from Apheresed Human Product
11:51

Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product

Published on: September 22, 2021

8.9K

Area of Science:

  • Hematology
  • Transfusion Medicine
  • Cellular Therapy

Background:

  • Hematopoietic progenitor cells (HPC) are typically collected via leukapheresis.
  • Anticoagulants are routinely used during leukapheresis to prevent circuit and product clotting.
  • Clotting of fresh HPC product post-collection is not a reported complication.

Observation:

  • A case of progressive clotting in a fresh, unprocessed HPC product from a matched unrelated donor is presented.
  • Initial observation revealed thin, thread-like white clots within the HPC bag.
  • Aseptic aliquoting led to rapid clot coalescence into a large, jelly-like mass within 60 minutes.

Findings:

  • The fresh HPC product exhibited spontaneous and rapid clot formation.
  • The clotting process was progressive, transforming small clots into a significant mass.
  • This observation challenges the assumption that fresh HPC products are immune to clotting before processing.

Implications:

  • This case suggests that fresh HPC products may be susceptible to clotting even without cryopreservation.
  • The findings indicate a potential need for anticoagulant addition to fresh HPC products before manipulation.
  • Further investigation into the mechanisms of spontaneous clotting in HPC products is warranted to ensure product viability and safety.